Pyxis Oncology Inc (NASDAQ:PYXS) has a beta value of 1.00 and has seen 2.07 million shares traded in the last trading session. The company, currently valued at $62.83M, closed the last trade at $1.02 per share which meant it lost -$0.04 on the day or -3.77% during that session. The PYXS stock price is -428.43% off its 52-week high price of $5.39 and 18.63% above the 52-week low of $0.83. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.59 million shares traded. The 3-month trading volume is 556.00K shares.
The consensus among analysts is that Pyxis Oncology Inc (PYXS) is Buy stock at the moment, with a recommendation rating of 1.33. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 2 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.3.
Pyxis Oncology Inc (NASDAQ:PYXS) trade information
Sporting -3.77% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PYXS stock price touched $1.02 or saw a rise of 12.07%. Year-to-date, Pyxis Oncology Inc shares have moved -34.62%, while the 5-day performance has seen it change 11.48%. Over the past 30 days, the shares of Pyxis Oncology Inc (NASDAQ:PYXS) have changed -15.70%. Short interest in the company has seen 7.34 million shares shorted with days to cover at 15.1.
Wall Street analysts have a consensus price target for the stock at $10, which means that the shares’ value could jump 89.8% from current levels. The projected low price target is $7.0 while the price target rests at a high of $10.0. In that case, then, we find that the current price level is -880.39% off the targeted high while a plunge would see the stock gain -586.27% from current levels.
Pyxis Oncology Inc (PYXS) estimates and forecasts
The company’s shares have lost -68.42% over the past 6 months. Revenue growth from the last financial year stood is estimated to be -100.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -74.92% over the past 5 years. Earnings growth for 2025 is a modest 11.83% while over the next 5 years, the company’s earnings are expected to increase by 5.26%.
PYXS Dividends
Pyxis Oncology Inc is expected to release its next earnings report on 2025-Mar-17 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Pyxis Oncology Inc (NASDAQ:PYXS)’s Major holders
Insiders own 23.72% of the company shares, while shares held by institutions stand at 40.06% with a share float percentage of 52.52%. Investors are also buoyed by the number of investors in a company, with Pyxis Oncology Inc having a total of 129.0 institutions that hold shares in the company. The top two institutional holders are DEEP TRACK CAPITAL, LP with over 4.18 million shares worth more than $13.85 million. As of 2024-06-30, DEEP TRACK CAPITAL, LP held 6.9164% of shares outstanding.
The other major institutional holder is LAURION CAPITAL MANAGEMENT LP, with the holding of over 3.86 million shares as of 2024-06-30. The firm’s total holdings are worth over $12.78 million and represent 6.3826% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . As of Dec 31, 2024 , the former fund manager holds about 2.10% shares in the company for having 1.29 shares of worth $1.32 million while later fund manager owns 1.26 shares of worth $1.28 million as of Mar 31, 2025 , which makes it owner of about 2.04% of company’s outstanding stock.
